American Association for Cancer Research
Browse

Data from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment

Posted on 2024-06-03 - 07:21
AbstractPurpose:

Pancreatic ductal adenocarcinoma (PDAC) is generally divided in two subtypes, classical and basal. Recently, single-cell RNA sequencing has uncovered the coexistence of basal and classical cancer cells, as well as intermediary cancer cells, in individual tumors. The latter remains poorly understood; here, we sought to characterize them using a multimodal approach.

Experimental Design:

We performed subtyping on a single-cell RNA sequencing dataset containing 18 human PDAC samples to identify multiple intermediary subtypes. We generated patient-derived PDAC organoids for functional studies. We compared single-cell profiling of matched blood and tumor samples to measure changes in the local and systemic immune microenvironment. We then leveraged longitudinally patient-matched blood to follow individual patients over the course of chemotherapy.

Results:

We identified a cluster of KRT17-high intermediary cancer cells that uniquely express high levels of CXCL8 and other cytokines. The proportion of KRT17high/CXCL8+ cells in patient tumors correlated with intratumoral myeloid abundance, and, interestingly, high protumor peripheral blood granulocytes, implicating local and systemic roles. Patient-derived organoids maintained KRT17high/CXCL8+ cells and induced myeloid cell migration in a CXCL8-dependent manner. In our longitudinal studies, plasma CXCL8 decreased following chemotherapy in responsive patients, while CXCL8 persistence portended worse prognosis.

Conclusions:

Through single-cell analysis of PDAC samples, we identified KRT17high/CXCL8+ cancer cells as an intermediary subtype, marked by a unique cytokine profile and capable of influencing myeloid cells in the tumor microenvironment and systemically. The abundance of this cell population should be considered for patient stratification in precision immunotherapy.

See related commentary by Faraoni and McAllister, p. 2297

CITE THIS COLLECTION

DataCite
No result found
or
Select your citation style and then place your mouse over the citation text to select it.

FUNDING

National Cancer Institute (NCI)

United States Department of Health and Human Services

U.S. Department of Veterans Affairs (VA)

Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM)

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

United States Department of Health and Human Services

National Institute of Allergy and Infectious Diseases (NIAID)

United States Department of Health and Human Services

SHARE

email

Usage metrics

Clinical Cancer Research

AUTHORS (46)

  • Eileen S. Carpenter
    Padma Kadiyala
    Ahmed M. Elhossiny
    Samantha B. Kemp
    Jay Li
    Nina G. Steele
    Rémy Nicolle
    Zeribe C. Nwosu
    Julia Freeman
    Henry Dai
    Daniel Paglia
    Wenting Du
    Katelyn Donahue
    Jacqueline Morales
    Paola I. Medina-Cabrera
    Monica E. Bonilla
    Lindsey Harris
    Stephanie The
    Valerie Gunchick
    Nicole Peterson
need help?